The latest news for pharma industry insiders.

The proposal aims to reduce out-of-pocket costs for a number of anti-obesity medications by 95%.

Results of the RESILIENT SMA study found that while taldefgrobep demonstrated clinically meaningful motor function improvements in patients with spinal muscular atrophy, the treatment arm did not achieve statistical significance at 48 weeks.

The latest news for pharma industry insiders.

CelloType produces more accurate results when analyzing high content tissue images.

Pathway is now the first and only FDA-approved companion diagnostic for identifying HER2-positive biliary tract cancer patients eligible for treatment with Ziihera.

The educational platform is targeted at HCPs and their staff.

The actor is part of a campaign for early colon cancer screening.

The latest news for pharma industry insiders.

Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.

The results say that the industry still lacks talent and skills in this area.

The latest news for pharma industry insiders.

The campaign also includes partnerships with other celebrities, including Lance Bass and Retta.

Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) provides a chemotherapy-free treatment option for patients with HER2-positive biliary tract cancer, addressing a critical unmet need with promising efficacy and improved quality of life.

Dorman previously served as head of Gilead Sciences’ U.S. Oncology Unit.

The drug, developed by UCB, is approved to treat adults with the inflammatory skin disease.

The latest news for pharma industry insiders.

Former Chief Oncology Officer and Executive Vice President, Chris Boshoff, MD, PhD, will assume the role and lead all R&D functions including oncology.

The latest news for pharma industry insiders.

Ron Lanton, Partner, Lanton Law, ways that the recent FDA PD-1 inhibitor label restrictions could influence future drug development strategies.

Ron Lanton, Partner, Lanton Law, discusses potential challenges that will come as a result of the FDA’s recent move to tighten label restrictions on PD-1 inhibitors for gastric cancers.

As skepticism surrounding AI fades, pharma industry execs are ready to embrace the technology.

The latest news for pharma industry insiders.

Syndax describes the drug as the first of its kind.